{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-063038","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.104006+00:00","generated_at":"2026-05-18T17:42:30.502882+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Protagonist Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor","bullets":["Harold Selick and Bryan Giraudo elected Class III directors with ~83% and ~79% of votes cast, respectively.","Non-binding advisory vote on executive compensation approved: 50.8M for, 2.9M against, 0.3M abstentions.","Ratification of Ernst & Young as independent auditor for FY 2025 approved: 55.5M for, 74k against, 0.4M abstentions.","No other proposals were submitted; broker non-votes were 1,918,517 for all director and say-on-pay items."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-063038","json":"https://secwatch.observer/filing/0001104659-25-063038.json","markdown":"https://secwatch.observer/filing/0001104659-25-063038.md","text":"https://secwatch.observer/filing/0001104659-25-063038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925063038/0001104659-25-063038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925063038/tm2518863d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:42:30.502882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}